Market Place
Sourcing Support
BNBX Launches Digital Asset Treasury Dashboard & Updates
28 Oct 2025 //
BUSINESSWIRE
Applied DNA To Trade As BNBX, Reflecting Digital Asset Strategy
06 Oct 2025 //
PHARMAWEB
Applied DNA Plans $58M Private Placement, BNB Treasury Push
29 Sep 2025 //
BUSINESSWIRE
Applied Dna Abstracts Chosen For Poster Presentations
23 Sep 2025 //
ACCESSWIRE
Applied DNA Complies with All Nasdaq Listing Requirements
07 Jul 2025 //
ACCESSWIRE
Applied DNA Announces 1-For-15 Reverse Stock Split on June 2
29 May 2025 //
ACCESSWIRE
Applied DNA reschedules webcast and call to June 17
29 May 2025 //
ACCESSWIRE
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
15 May 2025 //
ACCESSWIRE
Applied DNA to Announce Q2 Fiscal 2025 Results on May 15
14 May 2025 //
ACCESSWIRE
Applied DNA Submits Validation Package for H5 Bird Flu Test
26 Mar 2025 //
ACCESSWIRE
Applied DNA Announces 1-For-50 Reverse Stock Split On March 14
12 Mar 2025 //
ACCESSWIRE
Applied DNA Reports Q2 Fiscal Financial Results & Progress
13 Feb 2025 //
ACCESSWIRE
Applied DNA Urges Shareholders To Vote Before Feb 14 Meeting
11 Feb 2025 //
ACCESSWIRE
Applied DNA Completes Buildout of GMP Facility
10 Jan 2025 //
ACCESSWIRE
Applied DNA Reschedules Investor Update Call
08 Jan 2025 //
ACCESSWIRE
Applied DNA Customer Initiates Phase I CAR T-Cell Trial
18 Dec 2024 //
ACCESSWIRE
Applied DNA Announces Q4 2024 Results, Restructures to Prioritize
17 Dec 2024 //
ACCESSWIRE
Applied DNA to Report Q4 FY24 Results, Sets January Webcast
16 Dec 2024 //
ACCESSWIRE
Applied DNA Prices $6.5M Registered Offering & Private Placement
30 Oct 2024 //
ACCESSWIRE
Applied DNA Receives Linea DNA Follow-On Order For Cancer Diagnostic Application
17 Sep 2024 //
ACCESSWIRE
Applied DNA To Showcase Linea IVT Platform For GMP RNA Manufacturing At Summit
17 Sep 2024 //
ACCESSWIRE
Applied DNA Launches Mpox Clade I and Clade II Testing Service
11 Sep 2024 //
ACCESSWIRE
Applied DNA Submits Validation For Expanded Mpox Virus Assay In New York
23 Aug 2024 //
ACCESSWIRE
Applied DNA To Expand Linea Mpox Assay For Clade I 2023
19 Aug 2024 //
ACCESSWIRE
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
08 Aug 2024 //
ACCESSWIRE
Applied DNA To Report Q3 Fiscal 2024 Results On August 8
07 Aug 2024 //
ACCESSWIRE
Applied DNA To Showcase Linea IVT At mRNA-Based Therapeutics Summit
29 Jul 2024 //
ACCESSWIRE
Applied DNA Partners With GenXys To Deploy Clinical Decision Support PGx Testing
18 Jun 2024 //
ACCESSWIRE
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
10 May 2024 //
ACCESSWIRE
Applied DNA Enters into Agreement with Alphazyme
18 Mar 2024 //
ACCESSWIRE
Applied DNA Names Executive Director of Quality and cGMP Programs
07 Sep 2023 //
CONTRACT PHARMA
Applied DNA Files Patent Applications for Methods of Double-Stranded RNA Mitigation
23 Aug 2023 //
ACCESSWIRE
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results
10 Aug 2023 //
ACCESSWIRE
Applied DNA Acquires RNA Polymerase Developer Spindle Biotech
13 Jul 2023 //
ACCESSWIRE
Applied DNA Achieves Milestone for Large-Scale linearDNA Production
29 Mar 2023 //
BUSINESSWIRE
Applied DNA Submits Validation Package for Approval of PGx
22 Mar 2023 //
BUSINESSWIRE
Applied DNA Announces New York State Award Valued at Up To $1.5 Million
10 Feb 2023 //
BUSINESSWIRE
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
09 Feb 2023 //
BUSINESSWIRE
Applied DNA Announces Publication Validating Potential Use of linearDNA
05 Jan 2023 //
BUSINESSWIRE
